← Harmony Biosciences Holdings, Inc. HRMY
Market Price
$38.08
Market Cap
$2.23B
P/E Ratio
N/A
Revenue (FY 2025)
↑21.5% YoY
$868.45M
3-Yr CAGR: 25.6%
Net Income
↓-32.7% YoY
$290.30M
Net Margin: 33.4%
Free Cash Flow
↑59.1% YoY
$347.89M
FCF Yield: 15.60%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
8.0%
ROA: 22.8%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (HRMY)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2017 | $-10.8M | — | — | $-266.4M | — | — | — | $-111.5M | — | — |
| FY 2018 | $-86.5M | -700.9% | — | $-145.8M | +45.3% | — | — | $-304.5M | — | — |
| FY 2019 | $6.0M | +106.9% | $4.4M | $-239.5M | -64.3% | — | — | $-75.4M | $-75.6M | — |
| FY 2020 | $159.7M | +2,564.6% | $125.8M | $-56.4M | +76.5% | — | — | $-3.0M | $-3.0M | +96.0% |
| FY 2021 | $305.4M | +91.2% | $281.2M | $-14.7M | +73.9% | — | — | $98.6M | $98.3M | +3,389.6% |
| FY 2022 | $437.9M | +43.4% | $419.1M | $6.5M | +144.2% | — | — | $144.5M | $144.3M | +46.9% |
| FY 2023 | $582.0M | +32.9% | $558.3M | $484.8M | +7,358.5% | — | — | $219.4M | $219.1M | +51.8% |
| FY 2024 | $714.7M | +22.8% | $697.2M | $431.2M | -11.1% | — | — | $219.8M | $218.7M | -0.2% |
| FY 2025 | $868.5M | +21.5% | $853.8M | $290.3M | -32.7% | — | — | $348.2M | $347.9M | +59.1% |
Valuation
Market Price
$38.08
Market Cap
$2.23B
Enterprise Value
$1.92B
P/E Ratio
N/A
P/B Ratio
0.61
FCF Yield
15.60%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
98.31%
Operating Margin
24.00%
Net Margin
33.43%
Return on Equity (ROE)
8.01%
Return on Assets (ROA)
22.83%
Asset Turnover
0.68x
Revenue 3-Yr CAGR
25.64%
Financial Health & Liquidity
Current Ratio
2.73
Cash Ratio
151.81
Debt / Equity
0.122
Debt / Assets
0.346
Cash & Equivalents
$752.50M
Total Debt
$440.46M
Book Value / Share
$62.62
Cash Flow Efficiency
Operating Cash Flow
$348.20M
Capital Expenditures (CapEx)
$310.00K
Free Cash Flow
$347.89M
OCF / Revenue
40.09%
FCF / Revenue
40.06%
FCF 3-Yr CAGR
34.09%
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
$62.62
EPS YoY Growth
N/A
Balance Sheet (FY 2025)
Total Assets
$1.27B
Total Liabilities
$1.27B
Stockholders' Equity
$3.63B
Current Assets
$13.52M
Current Liabilities
$4.96M